QIAGEN today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The ...

Research sheds light on health outcomes and insurance coverage for patients treated with GLP-1s, and how technology is ...

For decades, Americans have relied on exit polls to illuminate the story of what happened on election night. By gathering ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported ...